Barclays Maintains Equal-Weight on Biogen, Lowers Price Target to $215
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Carter Gould maintains an Equal-Weight rating on Biogen (NASDAQ:BIIB) and lowers the price target from $230 to $215.
April 04, 2024 | 1:36 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Barclays maintains an Equal-Weight rating on Biogen and lowers the price target from $230 to $215.
The reduction in price target by Barclays, a major financial institution, could lead to a negative short-term sentiment among investors, potentially causing a decrease in Biogen's stock price.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100